What is myTomorrows?
myTomorrows operates as a critical intermediary in the healthcare sector, specializing in patient-centric solutions that facilitate access to clinical trials and expanded access programs. By leveraging real-world data and sophisticated recruitment services, the company empowers healthcare professionals and patients to navigate complex treatment landscapes. Its platform serves as a vital conduit for BioPharma organizations, streamlining the identification of eligible candidates for clinical studies and ensuring that innovative medical interventions reach those in need with greater speed and precision. The company's market position is defined by its dual focus on patient advocacy and clinical operational excellence.
How much funding has myTomorrows raised?
myTomorrows has raised a total of $47.3M across 4 funding rounds:
Angel/Seed
$2.2M
Unspecified
$5.6M
Private Equity
$10.5M
Private Equity
$29M
Angel/Seed (2014): $2.2M, investors not publicly disclosed
Unspecified (2014): $5.6M led by Balderton Capital LLP and Sofinnova Ventures
Private Equity (2017): $10.5M supported by Octopus Ventures, Sofinnova Partners, EQT Ventures, and Balderton Capital LLP
Private Equity (2025): $29M featuring Avego
Key Investors in myTomorrows
Avego
Avego is a multi-strategy investment firm dedicated to the healthcare sector, aiming to combine industry expertise and capital with entrepreneurial management to enhance patient outcomes.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability, acting as a hands-on company builder across the entire value chain.
Balderton Capital LLP
Balderton Capital is a London-based venture capital firm that raises dedicated funds to invest in early-stage, high-growth technology companies across Europe, supporting founders through global scale-up.
What's next for myTomorrows?
With this latest capital injection, myTomorrows is expected to scale its digital infrastructure and expand its footprint in the clinical trial management market. The strategic focus will likely shift toward enhancing its real-world data capabilities and deepening partnerships with global BioPharma entities to optimize trial recruitment cycles. As the company moves into this next phase of growth, it remains well-positioned to capitalize on the increasing demand for patient-centric clinical research models, potentially setting new standards for transparency and accessibility in the development of transformative medical therapies.
See full myTomorrows company page
